Effect of the TAAR1 Partial Agonist Ralmitaront on Presynaptic Dopamine Synthesis Capacity Measured Using [¹⁸F]DOPA PET in Naive and Cocaine-Treated Mice.

ABSTRACT:

Purpose

Elevated dopamine synthesis capacity is part of the pathophysiology of schizophrenia thought to underlie psychosis. Drugs that reduce this phenomenon could thus be potential treatments for these disorders. In this study, we evaluated the ability of the trace amine-associated receptor 1 (TAAR1) partial agonist ralmitaront to reduce presynaptic dopamine synthesis capacity.

Procedures

Ralmitaront (3 mg/kg, i.p.), a TAAR1 partial agonist, was evaluated using [¹⁸F]DOPA PET for its ability to modulate presynaptic dopamine synthesis capacity in naïve mice as well as mice in an induced hyperdopaminergic state following acute cocaine administration (20 mg/kg, i.p.).

Results

Cocaine treatment on its own did not induce elevated dopamine synthesis capacity when

SUBMITTER: Bonsall DR 

PROVIDER: S-EPMC11911367 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature